Improved Detection Sensitivity of an Antigen Test for SARS-CoV-2 Nucleocapsid Proteins with Thio-NAD Cycling

Biol Pharm Bull. 2021 Sep 1;44(9):1332-1336. doi: 10.1248/bpb.b21-00387. Epub 2021 Jun 19.

Abstract

Antigen tests for infectious diseases are inexpensive and easy-to-use, but the limit of detection (LOD) is generally higher than that of PCR tests, which are considered the gold standard. In the present study, we combined a sandwich enzyme-linked immunosorbent assay (ELISA) with thionicotinamide-adenine dinucleotide (thio-NAD) cycling to improve the LOD of antigen tests for coronavirus disease 2019 (COVID-19). For recombinant nucleocapsid proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the LOD of our ELISA with thio-NAD cycling was 2.95 × 10-17 moles/assay. When UV-irradiated inactive SARS-CoV-2 was used, the minimum detectable virions corresponding to 2.6 × 104 RNA copies/assay were obtained using our ELISA with thio-NAD cycling. The assay volume for each test was 100 µL. The minimum detectable value was smaller than that of the latest antigen test using a fluorescent immunoassay for SARS-CoV-2, indicating the validity of our detection system for COVID-19 diagnosis.

Keywords: antigen test; coronavirus disease 2019; nucleocapsid protein; severe acute respiratory syndrome coronavirus 2; thionicotinamide-adenine dinucleotide cycling; ultrasensitivity.

Publication types

  • Validation Study

MeSH terms

  • Antibodies, Viral*
  • Antigens, Viral
  • COVID-19 / diagnosis*
  • COVID-19 / virology
  • COVID-19 Testing / methods*
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Humans
  • Immunologic Tests
  • Limit of Detection
  • NAD / analogs & derivatives*
  • Nucleocapsid / analysis
  • Nucleocapsid Proteins / immunology*
  • SARS-CoV-2*
  • Sensitivity and Specificity

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Nucleocapsid Proteins
  • NAD
  • thionicotinamide adenine dinucleotide